Respiratory syncytial virus is a common, highly contagious illness that often causes mild upper respiratory symptoms, akin to a cold. In babies, particularly those with tiny airways, RSV can cause the ...

a new golden child could be emerging in the form of Beyfortus. During its first full year on the market, the respiratory syncytial virus (RSV) antibody easily broke the $1 billion sales threshold.

High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...

Get Your Free Sample Market Report: What is behind the incessant drive of the beyfortus global market ? The increasing incidence of RSV cases continues to propel the market ahead. RSV is an ...

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

Beyfortus needs two injections but, on the other hand, is also approved for use in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. I keep a slim copy ...

SK bioscience announced on the 14th that it has begun supplying the antibody injection for respiratory syncytial virus (RSV) prevention called "Beyfortus" from the French company Sanofi. Beyfortus can ...

Two RSV vaccines were approved for use in Australia ... are picking up the tab for Sanofi-Aventis’ nirsevimab (sold as Beyfortus) for infants. This is widely used, and funded, in the US and ...